Integra Laminoplasty System

K150469 · Seaspine, Inc. · NQW · Mar 23, 2015 · Orthopedic

Device Facts

• Record ID: K150469
• Device Name: Integra Laminoplasty System
• Applicant: Seaspine, Inc.
• Product Code: NQW · Orthopedic
• Decision Date: Mar 23, 2015
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 888.3050
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Integra Laminoplasty System is intended for use in the lower cervical and upper thoracic spine (C3 to T3) after laminoplasty procedures. The Integra Laminoplasty System is used to hold the allograft material in place in order to prevent the allograft material from expulsion, or impinging the spinal cord.

Device Story

Integra Laminoplasty System consists of titanium alloy plates and screws; used to secure allograft material to lamina following laminoplasty procedures in lower cervical/upper thoracic spine (C3-T3). System includes various plate sizes/shapes and screw configurations to accommodate patient anatomy; includes specialized implantation instruments. Used by surgeons in clinical/OR settings. Device prevents allograft expulsion and spinal cord impingement. Mechanical fixation device; no software or algorithm.

Clinical Evidence

No clinical testing was required to demonstrate equivalence. Bench testing only.

Technological Characteristics

Titanium alloy plates and screws; various sizes/shapes/configurations. Mechanical fixation orthosis. Sterility: Not specified. Standards: Static testing per ASTM F2193.

Indications for Use

Indicated for patients undergoing laminoplasty procedures in the lower cervical and upper thoracic spine (C3 to T3) to secure allograft material and prevent expulsion or spinal cord impingement.

Regulatory Classification

Identification

A spinal interlaminal fixation orthosis is a device intended to be implanted made of an alloy, such as stainless steel, that consists of various hooks and a posteriorly placed compression or distraction rod. The device is implanted, usually across three adjacent vertebrae, to straighten and immobilize the spine to allow bone grafts to unite and fuse the vertebrae together. The device is used primarily in the treatment of scoliosis (a lateral curvature of the spine), but it also may be used in the treatment of fracture or dislocation of the spine, grades 3 and 4 of spondylolisthesis (a dislocation of the spinal column), and lower back syndrome.

Predicate Devices

• Integra Laminoplasty System (K130830)

Reference Devices

• NuVasive (Leverage) Laminoplasty Fixation System (K091623)
• CENTERPIECE Plate Fixation System (K050082)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of a human figure in profile, with multiple overlapping faces suggesting a sense of community and interconnectedness.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

March 23, 2015

SeaSpine, Incoporated Ms. Michelle Willis Director, Regulatory Affairs 2302 La Mirada Drive Vista, California 92081

Re: K150469

Trade/Device Name: Integra® Laminoplasty System Regulation Number: 21 CFR 888.3050 Regulation Name: Spinal interlaminal fixation orthosis Regulatory Class: Class II Product Code: NQW Dated: February 17, 2015 Received: February 23, 2015

Dear Ms. Willis:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

{1}------------------------------------------------

Page 2 - Ms. Michelle Willis

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely vours.

# Lori A. Wiggins -S

for Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

### Indications for Use

510(k) Number (if known)

K150469

Device Name Integra® Laminoplasty System

Indications for Use (Describe)

The Integra Laminoplasty System is intended for use in the lower thoracic spine (C3 to T3) for laminoplasty procedures. The Integra Laminoplasty System is used to hold the allograft material in place in order to prevent the allograft material from expulsion, or impinging the spinal cord.

| Type of Use (Select one or both, as applicable) | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <div style="display:flex; align-items:center;"> <div style="margin-right:5px;"> <span style="font-size: 20px;">☑</span> </div> <span>Prescription Use (Part 21 CFR 801 Subpart D)</span> </div> | <div style="display:flex; align-items:center;"> <div style="margin-right:5px;"> <span style="font-size: 20px;">☐</span> </div> <span>Over-The-Counter Use (21 CFR 801 Subpart C)</span> </div> |

|| | Prescription Use (Part 21 CFR 801 Subpart D)

|__| Over-The-Counter Use (21 CFR 801 Subpart C)

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

# 510(k) Summary

## 1. Contact Details

| Applicant Name: | SeaSpine, Inc. (A subsidiary of Integra LifeSciences Corporation) |
|------------------------------------------|------------------------------------------------------------------------------------|
| Address:<br>Phone number:<br>Fax number: | 2302 La Mirada Drive, Vista, CA 92081<br>[phone]<br>[phone] |
| Contact person:<br>Email address: | Michelle Willis, - Director, Regulatory Affairs<br>[e-mail] |
| Date Prepared: | February 17, 2015 |

# 2. Device Name

| Trade Name: | Integra® Laminoplasty System |
|----------------------|----------------------------------------------------------------------------------------|
| Common Name: | Laminoplasty Plating System |
| Classification Name: | Spinal Interlaminal Fixation Orthosis (21 CFR 888.3050)<br>Product Code: NQW, Class II |

# 3. Legally Marketed Predicate Device(s)

| Predicate | 510(k) Number | Product Code | Trade Name | Manufacturer |
|-----------|---------------|--------------|-----------------------------------------------------|--------------------------------------|
| Primary | K130830 | NQW | Integra Laminoplasty System | SeaSpine, Inc. |
| Reference | K091623 | NQW | NuVasive (Leverage)<br>Laminoplasty Fixation System | NuVasive, Inc. |
| Reference | K050082 | NQW | CENTERPIECETM Plate Fixation System | Medtronic Sofamor Danek<br>USA, Inc. |

# 4. Device Description

The Integra Laminoplasty System consists of titanium alloy plates and screws that are attached to the lamina after a laminoplasty procedure. Implants are available in a range of sizes and shapes, as well as in various screw hole configurations to accommodate variations in patient anatomy. The system also includes instruments to assist with implantation, and a tray for organization and storage

{4}------------------------------------------------

K Page 2/2

## 5. Intended Use/Indications for use

The Integra Laminoplasty System is intended for use in the lower cervical and upper thoracic spine (C3 to T3) after laminoplasty procedures. The Integra Laminoplasty System is used to hold the allograft material in place in order to prevent the allograft material from expulsion, or impinging the spinal cord.

## 6. Substantial Equivalence Comparison

The Integra Laminoplasty System is substantially equivalent to the cited predicate devices in areas including intended use/indications for use, technological characteristics (operating principle, design, materials, sterility, manufacturing, etc.) and performance (mechanical safety).

## 7. Non-clinical Testing

The Integra Laminoplasty System demonstrated equivalent performance to the predicate systems through static testing per ASTM F2193.

## 8. Clinical Testing

No clinical testing was required to demonstrate equivalence.

### 9. Conclusions

The submitted data demonstrate that the Integra Laminoplasty System is as safe, as effective, and performs at least as safely and effectively as the cited legally marketed predicate devices.